Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and stability

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2024-11-26 DOI:10.1016/j.ejmech.2024.117106
Maximilian Gebhart, Mostafa Alilou, Ronald Gust, Stefan Salcher
{"title":"Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and stability","authors":"Maximilian Gebhart, Mostafa Alilou, Ronald Gust, Stefan Salcher","doi":"10.1016/j.ejmech.2024.117106","DOIUrl":null,"url":null,"abstract":"Drug resistance presents a significant challenge in cancer therapy, which has led to intensive research in resistance mechanisms and new therapeutic strategies. In chronic myeloid leukemia (CML), the introduction of Imatinib, the first tyrosine kinase inhibitor (TKI), drastically changed the outcome for patients. However, complete remission still cannot be achieved in a large number of patients in the long term. Therefore, there is a great interest in the design of new drugs to target TKI-resistant cancer cells. A promising approach to enhance the efficacy of Imatinib is the simultaneous application of cell death modulators derived from the Angiotensin II type 1 receptor blocker Telmisartan. The methyl ester (<strong>3a</strong>) of 4‘-((2-propyl-1<em>H</em>-benzo[<em>d</em>]imidazol-1-yl)methyl)-[1,1’-biphenyl]-2-carboxylic acid (LEAD-acid (<strong>4</strong>)), which is the structural core of Telmisartan, has already been shown to abolish the resistance of Imatinib in TKI-insensitive CML cells at a concentration of 5 μM. As the ester was expected to be unstable in a biological environment, this study attempted to increase the stability through structural modifications. The methyl group was exchanged for longer (<strong>3b</strong> (ethyl), <strong>3c</strong> (propyl), <strong>3d</strong> (butyl) and branched (<strong>3e</strong> (isopropyl), <strong>3f</strong> (<em>tert</em>-butyl)) alkyl chains as well as a phenyl (<strong>3g</strong>) and 4-phenoxyphenyl (<strong>3h</strong>) group. Furthermore, the esters were bioisosterically replaced with a respective substituted carboxamide (<strong>5a-h</strong>). The LEAD-amides (<strong>5a-h</strong>) showed high stability against esterases, while amidases cleaved only the carboxamides with short alkyl chains to a small extent. Esterases hydrolyzed the LEAD-alkylesters (<strong>3a-d</strong>) dependent on the chain length with τ<sub>½</sub> = 55-82 min. Esters with branched alkyl chains were stable and introduction of aromatic rings increased the half-life to τ<sub>½</sub> = 280 min and 360 min. In cell culture medium, only <strong>3a-d</strong> degraded to 67-78 % after 72 h. However, the uptake studies showed that approximatly 80 % of the esters were accumulated in the cell within the first 1-3 h of incubation. Therefore, it can be concluded that the intact LEAD-esters and LEAD-amides caused the biological effects. The compounds were non-cytotoxic and efficiently sensitized KD225 (K562-resistant) CML cells to Imatinib at a half-maximal sensitizing concentration (SC<sub>50</sub>) of 1.5-2.9 μM (ester derivatives) and 1.3-11.2 μM (amide derivatives).","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"62 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2024.117106","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Drug resistance presents a significant challenge in cancer therapy, which has led to intensive research in resistance mechanisms and new therapeutic strategies. In chronic myeloid leukemia (CML), the introduction of Imatinib, the first tyrosine kinase inhibitor (TKI), drastically changed the outcome for patients. However, complete remission still cannot be achieved in a large number of patients in the long term. Therefore, there is a great interest in the design of new drugs to target TKI-resistant cancer cells. A promising approach to enhance the efficacy of Imatinib is the simultaneous application of cell death modulators derived from the Angiotensin II type 1 receptor blocker Telmisartan. The methyl ester (3a) of 4‘-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1’-biphenyl]-2-carboxylic acid (LEAD-acid (4)), which is the structural core of Telmisartan, has already been shown to abolish the resistance of Imatinib in TKI-insensitive CML cells at a concentration of 5 μM. As the ester was expected to be unstable in a biological environment, this study attempted to increase the stability through structural modifications. The methyl group was exchanged for longer (3b (ethyl), 3c (propyl), 3d (butyl) and branched (3e (isopropyl), 3f (tert-butyl)) alkyl chains as well as a phenyl (3g) and 4-phenoxyphenyl (3h) group. Furthermore, the esters were bioisosterically replaced with a respective substituted carboxamide (5a-h). The LEAD-amides (5a-h) showed high stability against esterases, while amidases cleaved only the carboxamides with short alkyl chains to a small extent. Esterases hydrolyzed the LEAD-alkylesters (3a-d) dependent on the chain length with τ½ = 55-82 min. Esters with branched alkyl chains were stable and introduction of aromatic rings increased the half-life to τ½ = 280 min and 360 min. In cell culture medium, only 3a-d degraded to 67-78 % after 72 h. However, the uptake studies showed that approximatly 80 % of the esters were accumulated in the cell within the first 1-3 h of incubation. Therefore, it can be concluded that the intact LEAD-esters and LEAD-amides caused the biological effects. The compounds were non-cytotoxic and efficiently sensitized KD225 (K562-resistant) CML cells to Imatinib at a half-maximal sensitizing concentration (SC50) of 1.5-2.9 μM (ester derivatives) and 1.3-11.2 μM (amide derivatives).

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
避免慢性骨髓性白血病患者对伊马替尼产生耐药性:基于替米沙坦的新型细胞死亡调节剂具有更好的活性和稳定性
耐药性是癌症治疗中的一个重大挑战,它促使人们深入研究耐药机制和新的治疗策略。在慢性髓性白血病(CML)中,第一种酪氨酸激酶抑制剂(TKI)伊马替尼的问世极大地改变了患者的预后。然而,大量患者仍无法长期获得完全缓解。因此,人们对设计针对 TKI 耐药癌细胞的新药产生了浓厚的兴趣。提高伊马替尼疗效的一个可行方法是同时应用从血管紧张素 II 1 型受体阻滞剂替米沙坦中提取的细胞死亡调节剂。作为替米沙坦的结构核心,4'-((2-丙基-1H-苯并[d]咪唑-1-基)甲基)-[1,1'-联苯]-2-羧酸(LEAD-acid (4))的甲酯(3a)已被证明能在 5 μM 浓度下消除对 TKI 不敏感的 CML 细胞对伊马替尼的耐药性。由于预计该酯在生物环境中不稳定,本研究试图通过结构修饰来提高其稳定性。甲基被换成了较长的(3b(乙基)、3c(丙基)、3d(丁基)和支链(3e(异丙基)、3f(叔丁基))烷基链,以及苯基(3g)和 4-苯氧基苯基(3h)。此外,这些酯还被各自取代的羧酰胺(5a-h)生物异构取代。LEAD 酰胺(5a-h)对酯酶表现出很高的稳定性,而酰胺酶只在很小程度上裂解短烷基链的羧酰胺。酯酶水解 LEAD 烷醇酯(3a-d)的时间取决于链长,τ½ = 55-82 分钟。具有支化烷基链的酯是稳定的,引入芳香环后,半衰期延长至 τ½ = 280 分钟和 360 分钟。在细胞培养基中,只有 3a-d 在 72 小时后降解到 67-78%。然而,吸收研究表明,在培养的最初 1-3 小时内,细胞中积累了大约 80%的酯。因此,可以得出结论:完整的 LEAD-酯和 LEAD-酰胺产生了生物效应。这些化合物无细胞毒性,能有效地使 KD225(K562 抗性)CML 细胞对伊马替尼敏感,半最大敏感浓度(SC50)分别为 1.5-2.9 μM(酯类衍生物)和 1.3-11.2 μM(酰胺类衍生物)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
Editorial Board Contents continued Graphical abstract TOC Graphical abstract TOC Diastereoselective synthesis and biological evaluation of new fluorine-containing α-aminophosphonates as anticancer agents and scaffold to human urokinase plasminogen activator inhibitors
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1